SC&A Draft: Review of the K-25 Gaseous Diffusion Plant Site
Total Page:16
File Type:pdf, Size:1020Kb
May 31, 2007 Mr. David Staudt Center for Disease Control and Prevention Acquisition and Assistance Field Branch Post Office Box 18070 626 Cochrans Mill Road – B-140 Pittsburgh, PA 15236-0295 Re: Contract No. 200-2004-03805, Task Order 1: Transmittal of Draft SCA-TR-TASK1-0017, K-25 Gaseous Diffusion Plant Site Profile Review Dear Mr. Staudt: SC&A, Inc. is please to submit its draft report titled K-25 Gaseous Diffusion Plant Site Profile Review, SCA-TR-TASK1-0017. This report was submitted for Privacy Act (PA) review on March 9, 2007, and has been revised to accommodate that review. This report is considered pre- decisional and is being submitted to the Advisory Board for review. Should you have any questions, please contact me at 732-530-0104. Sincerely, John Mauro, PhD, CHP Project Manager cc: P. Ziemer, PhD, Board Chairperson A. Makhijani, PhD, SC&A Advisory Board Members H. Behling, SC&A L. Wade, PhD, NIOSH M. Thorne, SC&A L. Elliott, NIOSH H. Chmelynski, SC&A J. Neton, PhD, NIOSH J. Fitzgerald, Saliant S. Hinnefeld, NIOSH J. Lipsztein, SC&A L. Homoki-Titus, NIOSH K. Robertson-DeMers, CHP, Saliant A. Brand, NIOSH S. Ostrow, PhD, SC&A J. Broehm, NIOSH K. Behling, SC&A L. Shields, NIOSH T. Bell, Saliant Project File (ANIOS/001/17) 1608 SPRING HILL ROAD, SUITE 400 • VIENNA, VIRGINIA • 22182 • 703.893.6600 • FAX 703.821.8236 Draft ADVISORY BOARD ON RADIATION AND WORKER HEALTH National Institute for Occupational Safety and Health K-25 Gaseous Diffusion Plant Site Profile Review Contract No. 200-2004-03805 Task Order No. 1 SCA-TR-TASK1-0017 Prepared by S. Cohen & Associates 1608 Spring Hill Road, Suite 400 Vienna, Virginia 22182 Saliant, Inc. 5579 Catholic Church Road Jefferson, Maryland 21755 May 2007 Disclaimer This document is made available in accordance with the unanimous desire of the Advisory Board on Radiation and Worker Health (ABRWH) to maintain all possible openness in its deliberations. However, the ABRWH and its contractor, SC&A, caution the reader that at the time of its release, this report is pre-decisional and has not been reviewed by the Board for factual accuracy or applicability within the requirements of 42 CFR 82. This implies that once reviewed by the ABRWH, the Board’s position may differ from the report’s conclusions. Thus, the reader should be cautioned that this report is for information only and that premature interpretations regarding its conclusions are unwarranted. Effective Date: Revision No. Document No. Page No. May 31, 2007 0 SCA-TR-TASK1-0017 2 of 191 S. Cohen & Associates: Document No. SCA-TR-TASK1-0017 Technical Support for the Advisory Board on Effective Date: Radiation and Worker Health Review of Draft — May 31, 2007 NIOSH Dose Reconstruction Program Revision No. 0 – DRAFT Page 1 of 191 K-25 GASEOUS DIFFUSION PLANT SITE PROFILE REVIVEW Supersedes: Task Manager: N/A ________________________ Date: ___________ Joseph Fitzgerald Project Manager: ________________________ Date: ___________ John Mauro NOTICE: This report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Worker Health for factual accuracy or applicability within the requirements of 42 CFR 82. Effective Date: Revision No. Document No. Page No. May 31, 2007 0 SCA-TR-TASK1-0017 3 of 191 TABLE OF CONTENTS Acronyms and Abbreviations ..........................................................................................................5 1.0 Executive Summary.............................................................................................................9 1.1 Summary of Strengths............................................................................................11 1.2 Summary of Findings.............................................................................................12 1.2.1 Primary Findings........................................................................................12 1.2.2 Secondary Findings....................................................................................15 1.3 Opportunities for Improvement .............................................................................16 2.0 Scope and Introduction ......................................................................................................20 2.1 Review Scope.........................................................................................................20 2.2 Review Approach...................................................................................................21 2.3 Report Organization...............................................................................................22 3.0 Assessment Criteria and Methods......................................................................................24 3.1 Objectives ..............................................................................................................24 3.1.1 Objective 1: Completeness of Data Sources.............................................24 3.1.2 Objective 2: Technical Accuracy..............................................................24 3.1.3 Objective 3: Adequacy of Data.................................................................25 3.1.4 Objective 4: Consistency among Site Profiles..........................................25 3.1.5 Objective 5: Regulatory Compliance........................................................25 4.0 Site Profile Strengths .........................................................................................................29 4.1 Internal Dose TBD Strengths.................................................................................29 4.2 External Dose TBD Strengths................................................................................29 4.3 Medical Dose Strengths .........................................................................................30 4.4 Environmental Dose TBD Strengths .....................................................................30 5.0 Vertical Issues....................................................................................................................31 5.1 Issue 1: More Guidance is Needed on Appropriate Enrichment when interpreting Uranium Bioassay Mass Concentration Data.....................................31 5.2 Issue 2: No Default Absorption (Solubility) Classes for Any of the Intakes are Identified ..........................................................................................................32 5.3 Issue 3: The Default Isotopic Distribution does Not Appear to be Claimant Favorable................................................................................................................34 5.4 Issue 4: There is General Inconsistency or Lack of Complete Radionuclide Information for Facilities in the TBD Tables ........................................................35 5.5 Issue 5: Lack of Incident Information May be a Problem for Accuracy and Claimant-Favorable Internal Dose Reconstruction................................................36 5.6 Issue 6: Coworker Data Use and Approach for Unmonitored Employees May not be Appropriate.........................................................................................37 5.7 Issue 7: Uranium Cylinder Storage Yard Dose May be Underestimated and Neutron Dose May have been Missed ...................................................................39 NOTICE: This report is pre-decisional and has not been reviewed by the Advisory Board on Radiation and Worker Health for factual accuracy or applicability within the requirements of 42 CFR 82. Effective Date: Revision No. Document No. Page No. May 31, 2007 0 SCA-TR-TASK1-0017 4 of 191 5.8 Issue 8: Until 1980, Some dosimeters were only processed upon request resulting in ambiguity regarding the construction of doses in the early years.......40 5.9 Issue 9: Chronic Neutron Exposure Opportunities May have been Overlooked.............................................................................................................40 5.10 Issue 10: Potential Exposure to Tc-99 Beta were Not Recorded by Dosimeters and are Not Addressed in the TBD.....................................................41 5.11 Issue 11: Reliance on a Single Neutron-to-Photon Ratio for the Entire Plant is Questionable.......................................................................................................42 5.12 Issue 12: All Beta Dosimetry was based on a Uranium Slab Calibration ............42 5.13 Secondary Issues....................................................................................................43 5.13.1 Secondary Issue 1: There is a Lack of Guidance on Bioassay Interpretation..............................................................................................43 5.13.2 Secondary Issue 2: There is No Comparison between Measured and Predicted Environmental Dose............................................................45 5.13.3 Secondary Issue 3: The TBDs do not provide a Consistent Time Period for the Processing of RU at K-25. ..................................................45 5.13.4 Secondary Issue 4: The TBD Does Not Adequately Define Frequency and Assess All Types of X-rays in Occupational Medical Exposure. ...................................................................................................46 5.13.5 Secondary Issue 5: Techniques and Protocols Increase Uncertainty of Dose Conversion Factors Listed in the TBD.........................................48 5.14 Review of Technical Support Documents .............................................................50